Chromosome sensitivity to bleomycin in patients with dominantly inherited and sporadic tumors
Language English Country Slovakia Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
7688869
Knihovny.cz E-resources
- MeSH
- Bleomycin pharmacology MeSH
- Chromatids drug effects MeSH
- Chromosome Aberrations * MeSH
- Neoplastic Syndromes, Hereditary genetics MeSH
- Child MeSH
- Genes, Dominant * MeSH
- Adult MeSH
- G2 Phase MeSH
- Cells, Cultured MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Multiple Endocrine Neoplasia genetics MeSH
- Myelodysplastic Syndromes genetics MeSH
- Thyroid Neoplasms genetics MeSH
- Neurofibromatosis 1 genetics MeSH
- DNA Damage MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Age Factors MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Bleomycin MeSH
G2 chromosomal sensitivity to bleomycin (30 micrograms/ml) was tested in PHA-stimulated lymphocytes of healthy subjects and in patients with familial and sporadic tumors. These were multiple endocrine neoplasias (MEN) types 1, 2A and 2B, familial medullar thyroid cancer, Recklinghausen neurofibromatosis type I, sporadic and hereditary malignant tumors, and a preleukemic disorder, the myelodysplastic syndrome. Control subjects were either young (15-20), middle-aged (28-49) or old (70-83 years). Cells from old healthy subjects and from subjects with MEN 1 showed increased sensitivity to clastogenic effects of bleomycin. All the remaining investigated groups were insignificantly different from controls. Our data suggest that in contrast with recessively inherited syndromes with chromosome instability the mutagen hypersensitivity, as evaluated by the extent of chromosomal damage, is not a feature of most dominantly inherited tumor syndromes.
